GEN News Highlights: Jul 14, 2011

DVS Sciences Raises $14.6M for Multiparameter Single-Cell Mass Cytometry Platform

DVS Sciences Raises $14.6M for Multiparameter Single-Cell Mass Cytometry Platform

Firm claims CyTOF MAXPAR System will enable analysis of up to 100 labels in a single sample.[© Bobby4237 - Fotolia.com]

(Page 1 of 1)

    University of Toronto spin-out DVS Sciences raised $14.6 million in a Series A round of financing with institutional investors. The funds will be used to speed commercial manufacturing scale-up of the firm’s flagship CyTYOF®-MAXPAR®.

    DVS claims the CyTOF Mass Cytometer is the first inorganic mass spectrometer specifically designed for use for multiparametric single-cell analysis. It uses atomic mass spectrometry to allow the independent detection of metal-labeled antibodies based on currently available MAXPAR kits and two DNA intercalators. The firm says the CyTOF technology will potentially enable analysis of up to 100 stable isotope labels in a single sample.

    “The complete solution comprises a high-throughput mass cytometer for individual cell analysis, CyTOF, and a suite of MAXPAR reagents, which include stable-isotope-tagged antibodies,” explains Andrew Schwab, managing partner at investment firm 5AM Ventures. “The CyTOF technology eliminates the inherent spectral overlap issues and enables quantative, highly multibiomarker analysis for scientific research, with potential applications in clinical trials and personalized medicine."

    The CyTOF and MAXPAR technologies were originally developed by scientists at MDS Sciex (now AB Sciex) who subsequently moved to the University of Toronto to further develop the platform.  All the resulting IP has been licensed to DVS Sciences.

    The CyTOF workflow starts with the introduction of individual cells stained with metal-conjugated antibodies and metallointercalators into an Inductively Coupled Plasma, were they are atomized and ionized. The atomic ions are then extracted into the ion optics and time-of-flight regions where they are separated by mass and counted.

    The elemental signature of the cell includes the element tags introduced with the antibodies and metallointercalators. The presence of the metal tag indicates that the antibody found and bound the target biomarker, and the intensity of the signal is directly proportional to the number of antibodies bound per cell (ABC).

    The elemental composition of each cell is separately analyzed. DVS claims that in a typical cell-analysis experiment, four minutes of raw data collection is sufficient for analysis of 100,000 cells independent of the number of metal tags (one or all 33).

    The firm offers MAXPAR antibody or intracellular protein labeling reagent kits for 33 different metals. The kits utilize a traditional approach of adding a metal tag using disulfide reduction (typically in the Fc region of the antibody) through a maleimide linker. DVS says the labeling methods are simple and can be completed in 2.5 hours; labeled antibodies are then stable for approximately six months after preparation.


Related content

GEN News Highlights

Insight & Intelligence™

GEN Articles

Application Notes

Webinars

GEN Podcasts

Video Channel

New Products

Best of the Web

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll